Hib-DTaP-poliovirus vaccine - GlaxoSmithKline

Drug Profile

Hib-DTaP-poliovirus vaccine - GlaxoSmithKline

Alternative Names: Cinquerix; DTPa-IPV-Hib; Hib-DTP-acellular-poliovirus vaccine - GlaxoSmithKline; Infanrix IPV Hib; Infanrix-IPV-HiB

Latest Information Update: 05 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 04 Jun 2015 No recent reports of development identified - Phase-III for Diphtheria (In infants, Prevention) in China (IM)
  • 04 Jun 2015 No recent reports of development identified - Phase-III for Haemophilus infections (In infants, Prevention) in China (IM)
  • 04 Jun 2015 No recent reports of development identified - Phase-III for Pertussis (In infants, Prevention) in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top